{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:43:18Z","timestamp":1780105398297,"version":"3.54.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-025-06056-1","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T08:58:11Z","timestamp":1741165091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and effectiveness of a biosimilar somatropin (Cinnatropin\u00ae) in children and adolescents receiving growth hormone therapy over 1\u00a0year: a registry-based phase IV study"],"prefix":"10.1007","volume":"184","author":[{"given":"Ali","family":"Rabbani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Razzaghy-Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Karamizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahin","family":"Hashemipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahim","family":"Vakili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aria","family":"Setoodeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Alaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robabeh","family":"Ghergherehchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadab","family":"Salehpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Aminzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Talea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Zaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forough","family":"Saki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araz","family":"Sabzvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1246-8969","authenticated-orcid":false,"given":"Hamidreza","family":"Kafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"6056_CR1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00024677-200403010-00006","volume":"3","author":"R Lanes","year":"2004","unstructured":"Lanes R (2004) Long-term outcome of growth hormone therapy in children and adolescents. Treat Endocrinol 3:53\u201366","journal-title":"Treat Endocrinol"},{"key":"6056_CR2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.yapd.2022.03.005","volume":"69","author":"M Danowitz","year":"2022","unstructured":"Danowitz M, Grimberg A (2022) Clinical indications for growth hormone therapy. Adv Pediatr 69:203\u2013217","journal-title":"Adv Pediatr"},{"key":"6056_CR3","unstructured":"Olarescu NC, Gunawardane K, Hansen TK,\u00a0M\u00f8ller N, J\u00f8rgensen JOL (2019)\u00a0Normal physiology of growth hormone in adults. In: Feingold KR, Anawalt B, Blackman MR, et al., (eds). Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279056\/. Accessed 2 Mar 2025"},{"key":"6056_CR4","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.105028","volume":"126","author":"R Kingston","year":"2021","unstructured":"Kingston R, Sioris K, Gualtieri J, Brutlag A, Droege W, Osimitz T (2021) Post-market surveillance of consumer products: framework for adverse event management. Regul Toxicol Pharmacol 126:105028","journal-title":"Regul Toxicol Pharmacol"},{"key":"6056_CR5","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1161\/01.CIR.0000134694.78653.B6","volume":"109","author":"R Mehran","year":"2004","unstructured":"Mehran R, Leon MB, Feigal DA, Jefferys D, Simons M, Chronos N, Fogarty TJ, Kuntz RE, Baim DS, Kaplan AV (2004) Post-market approval surveillance: a call for a more integrated and comprehensive approach. Circulation 109:3073\u20133077","journal-title":"Circulation"},{"key":"6056_CR6","unstructured":"Centers for Disease Control and Prevention (2024). CDC growth charts data files. Available from: https:\/\/www.cdc.gov\/growthcharts\/cdc-data-files.htm. Accessed 2 June 2024."},{"key":"6056_CR7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112:90\u201392","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"6056_CR8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory activities (MedDRA). Drug Saf 20:109\u2013117","journal-title":"Drug Saf"},{"key":"6056_CR9","unstructured":"WHO (2013) The use of the WHO-UMC system for standardised case causality assessment. https:\/\/www.who.int\/publications\/m\/item\/WHO-causality-assessment. Accessed 5 June 2024."},{"key":"6056_CR10","unstructured":"ICH (2001) Maintenance of the ICH guideline on clinical safety data management: individual case safety reports E2B(R2). https:\/\/admin.ich.org\/sites\/default\/files\/inline-files\/E2B_R2_Guideline.pdf. Accessed 5 June 2024."},{"key":"6056_CR11","first-page":"538","volume":"27","author":"G Schumock","year":"1992","unstructured":"Schumock G, Thornton J (1992) Focusing on the preventability of adverse drug reactions. Hosp Pharm 27:538\u2013538","journal-title":"Hosp Pharm"},{"key":"6056_CR12","unstructured":"Richmond EJ, Rogol AD (2008) Diagnosis of growth hormone deficiency in children. Rose BD (edi). UpToDate https:\/\/www.uptodate.com\/contents\/diagnosis-of-growth-hormone-deficiency-in-children. Accessed 2 Mar 2025"},{"key":"6056_CR13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2042018813479644","volume":"4","author":"R Pf\u00e4ffle","year":"2013","unstructured":"Pf\u00e4ffle R, Schwab KO, Marginean O, Walczak M, Szalecki M, Schuck E, Zabransky M, Zucchini S (2013) Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope\u00ae in children requiring growth hormone treatment. Ther Adv Endocrinol Metab 4:3\u201311","journal-title":"Ther Adv Endocrinol Metab"},{"key":"6056_CR14","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1007\/s00431-022-04409-8","volume":"181","author":"P Backeljauw","year":"2022","unstructured":"Backeljauw P, Kanumakala S, Loche S, Schwab KO, Miller BS, Levy R, McCormick K, Zouater H, Zabransky M, Campbell K (2022) Safety and effectiveness of Omnitrope\u00ae(somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data. Eur J Pediatr 181:2367\u20132378","journal-title":"Eur J Pediatr"},{"key":"6056_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1687-9856-2012-1","volume":"2012","author":"PA Lee","year":"2012","unstructured":"Lee PA, Ross J, Germak JA, Gut R (2012) Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program\u00ae registry. Int J Pediatr Endocrinol 2012:1\u20138","journal-title":"Int J Pediatr Endocrinol"},{"key":"6056_CR16","first-page":"29","volume":"91","author":"A Al Shaikh","year":"2020","unstructured":"Al Shaikh A, Daftardar H, Alghamdi AA, Jamjoom M, Awidah S, Ahmed ME, Soliman AT (2020) Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center. Acta Bio Medica: Atenei Parmensis 91:29","journal-title":"Acta Bio Medica: Atenei Parmensis"},{"key":"6056_CR17","doi-asserted-by":"crossref","first-page":"e2717","DOI":"10.1210\/clinem\/dgac220","volume":"107","author":"CL Deal","year":"2022","unstructured":"Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, Kim H-S, Ko C, Malievskiy O, Cara JF (2022) Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab 107:e2717\u2013e2728","journal-title":"J Clin Endocrinol Metab"},{"key":"6056_CR18","volume":"13","author":"J Yuan","year":"2022","unstructured":"Yuan J, Fu J, Wei H, Zhang G, Xiao Y, Du H, Gu W, Li Y, Chen L, Luo F (2022) A randomized controlled phase 3 study on the efficacy and safety of recombinant human growth hormone in children with idiopathic short stature. Front Endocrinol 13:864908","journal-title":"Front Endocrinol"},{"key":"6056_CR19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000491016","volume":"90","author":"WY Chung","year":"2018","unstructured":"Chung WY, Yoo H-W, Hwang JS, Ko CW, Kim H-S, Jin D-K, Lee K-H, Han H-S, Paranchothy P, Suh B-K (2018) Effect of growth hormone therapy on height velocity in Korean children with idiopathic short stature: a phase III randomised controlled trial. Horm Res Paediatr 90:44\u201353","journal-title":"Horm Res Paediatr"},{"key":"6056_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1687-9856-2015-1","volume":"2015","author":"JL Ross","year":"2015","unstructured":"Ross JL, Lee PA, Gut R, Germak J (2015) Increased height standard deviation scores in response to growth hormone therapy to near-adult height in older children with delayed skeletal maturation: results from the ANSWER Program. Int J Pediatr Endocrinol 2015:1\u20139","journal-title":"Int J Pediatr Endocrinol"},{"key":"6056_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1687-9856-2011-1","volume":"2011","author":"PA Lee","year":"2011","unstructured":"Lee PA, Germak J, Gut R, Khutoryansky N, Ross J (2011) Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program\u00ae. Int J Pediatr Endocrinol 2011:1\u20137","journal-title":"Int J Pediatr Endocrinol"},{"key":"6056_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13052-016-0302-3","volume":"42","author":"L Iughetti","year":"2016","unstructured":"Iughetti L, Tornese G, Street ME, Napoli F, Giavoli C, Antoniazzi F, Stagi S, Luongo C, Azzolini S, Ragusa L (2016) Long-term safety and efficacy of Omnitrope\u00ae, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study. Ital J Pediatr 42:1\u20137","journal-title":"Ital J Pediatr"},{"key":"6056_CR23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40618-020-01331-4","volume":"44","author":"L Iughetti","year":"2021","unstructured":"Iughetti L, Antoniazzi F, Giavoli C, Bona G, Aversa T, Greggio N, Guazzarotti L, Minelli R, Perrone L, Persani L (2021) Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort. J Endocrinol Invest 44:493\u2013503","journal-title":"J Endocrinol Invest"},{"key":"6056_CR24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1210\/jc.2009-0178","volume":"95","author":"J Bell","year":"2010","unstructured":"Bell J, Parker K, Swinford R, Hoffman A, Maneatis T, Lippe B (2010) Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 95:167\u2013177","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06056-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06056-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06056-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T13:12:43Z","timestamp":1743081163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06056-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["6056"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06056-1","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"13 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational study, and the data used in this article is based on the routine practice of physicians. So, there was no need to obtain an ethical code as no intervention was done for performing the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Hamidreza Kafi is the head of the medical department of Orchid Pharmed Company which is in collaboration with CinnaGen Company with respect to conducting clinical trials. Araz Sabzvari is a member of CinnaGen medical biotechnology research center. This research center collaborates with universities and researchers all over the world with regards to research and development of medications and health issues. Hamidreza Kafi is the employee of the company, which could potentially introduce bias. However, the data collection and analysis were done by separate individuals to minimize bias and to ensure the integrity of the study. Other authors have no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing\u00a0interests"}}],"article-number":"226"}}